MediWound (MDWD) Stock Price, News & Analysis

Company Overview

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue. NexoBrid has received regulatory approval in the European Union and by the U.S. Food and Drug Administration for use in adults with severe thermal burns. MediWound is also advancing EscharEx™, a topical therapy aimed at debriding chronic and hard-to-heal wounds, currently undergoing pivotal clinical trials to expand its therapeutic portfolio.

MediWound’s commercial reach spans North America, Europe and other international markets through a network of strategic distribution partners. In the United States, the company supports its sales efforts with a dedicated subsidiary and field-based clinical specialists, while in Europe it works with established distributors to ensure product availability and regulatory compliance. The company continues to explore additional indications and territories to broaden access to its enzymatic treatments.

Leadership at MediWound is spearheaded by Chief Executive Officer Dan Rosenwasser, who has guided the company’s strategic expansion and commercialization initiatives. Under his direction, MediWound has strengthened its manufacturing capabilities and fortified its clinical pipeline. The management team’s combined expertise in biotechnology, regulatory affairs and commercial operations underpins the company’s mission to deliver advanced wound care solutions to patients worldwide.

Key Stats

• Today's Range: $16.08 to $16.93
• 50-Day Range: $16.29 to $21.09
• 52-Week Range: $14.14 to $22.50
• Volume: 9,490 shs
• Average Volume: 74,628 shs
• Market Capitalization: $175.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.25
• Consensus Rating: Moderate Buy

MediWound Stock Analysis - MarketRank™

MediWound scored higher than 32% of companies evaluated by MarketBeat, and ranked 804th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MediWound has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

MediWound has a consensus price target of $32.25, representing about 98.0% upside from its current price of $16.29.

Amount of Analyst Coverage

MediWound has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MediWound are expected to grow in the coming year, from ($2.66) to ($2.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MediWound is -6.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MediWound is -6.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MediWound has a P/B Ratio of 5.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.77% of the float of MediWound has been sold short.

Short Interest Ratio / Days to Cover

MediWound has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.

Change versus previous month

Short interest in MediWound has recently decreased by 2.15%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MediWound does not currently pay a dividend.

Dividend Growth

MediWound does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.77% of the float of MediWound has been sold short.

Short Interest Ratio / Days to Cover

MediWound has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.

Change versus previous month

Short interest in MediWound has recently decreased by 2.15%, indicating that investor sentiment is improving.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MediWound insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.20% of the stock of MediWound is held by insiders.

Percentage Held by Institutions

46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MDWD Stock Analysis - Frequently Asked Questions

How have MDWD shares performed this year?

MediWound's stock was trading at $17.80 at the beginning of the year. Since then, MDWD shares have decreased by 8.5% and is now trading at $16.29.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) released its quarterly earnings results on Thursday, August, 14th. The biopharmaceutical company reported ($1.23) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.68. The biopharmaceutical company earned $5.71 million during the quarter, compared to analysts' expectations of $5.68 million. MediWound had a negative net margin of 142.18% and a negative trailing twelve-month return on equity of 96.71%.
Read the conference call transcript.

When did MediWound's stock split?

Shares of MediWound reverse split on the morning of Tuesday, December 20th 2022.The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Who are MediWound's major shareholders?

Top institutional shareholders of MediWound include Yelin Lapidot Holdings Management Ltd. (7.56%), Rosalind Advisors Inc. (3.77%), Silverberg Bernstein Capital Management LLC (1.36%) and Geode Capital Management LLC (0.92%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MediWound investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MDWD
• CIK: 1593984
• Web: www.mediwound.com
• Phone: 972779714100
• Fax: 972-77-971-4111
• Employees: 80
• Year Founded: 2001

Price Target and Rating

• Average Price Target for MediWound: $32.25
• High Price Target: $39.00
• Low Price Target: $25.00
• Potential Upside/Downside: +98.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.22 million
• Net Margins: -142.18%
• Pretax Margin: -141.77%
• Return on Equity: -96.71%
• Return on Assets: -39.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.48
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: $20.22 million
• Price / Sales: 8.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.89 per share
• Price / Book: 5.64

Miscellaneous

• Outstanding Shares: 10,810,000
• Free Float: 9,814,000
• Market Cap: $176.09 million
• Optionable: Optionable
• Beta: 0.25